Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells

Fig. 3

WZ35 and cisplatin combination activated p38 and JNK signaling pathways. (a-b) SGC-7901 or BGC-823 cells were treated with WZ35 and cisplatin combination for the indicated times, the protein levels of p-p38, p38, p-JNK and JNK were determined by western blot. GAPDH was used as the internal control. (c-d) SGC-7901 or BGC-823 cells were treated with WZ35 or cisplatin alone or their combination at the indicated doses. At 12 h after treatment, the protein levels of p-p38, p38, p-JNK and JNK were determined by western blot. GAPDH was used as the internal control. (e) SGC-7901 or BGC-823 cells were pretreated with BMS-582949 (10 μM) or SP600125 (20 μM) for 2 h before exposure to WZ35 and cisplatin combination for 24 h, the cell viability was determined by MTT assay. (f) SGC-7901 or BGC-823 cells were pretreated with BMS-582949 (10 μM) or SP600125 (20 μM) for 2 h before exposure to WZ35 and cisplatin combination for 24 h, percentage of cell apoptosis was determined by flow cytometry. The percentage of apoptotic cells in the treatment groups was calculated. Data represent similar results from three independent experiments. (* p < 0.05, ** p < 0.01)

Back to article page